Dragon Pharma, Europe
1-Test Cyp 100
Injection · 100 mg/ml · 10 ml
Compound ID
Dihydroboldenone Cypionate
Dosage
100–200 mg/week
Concentration
100 mg/mL
Drug Class
Injectable
Half-life
4–5 days
Properties
Product overview
Dragon Pharma Dihydroboldenone Cypionate 100mg — Premium Injectable Anabolic for Dense Lean Tissue, Grainy Hardness & Estrogen-Free Physique Development
Dragon Pharma Dihydroboldenone Cypionate 100mg represents a sophisticated evolution in injectable anabolic engineering, designed for the discerning physique athlete who prioritizes tissue quality, muscular density, and aesthetic clarity over chaotic rapid bulk. Chemically distinct from its Boldenone parent compound through 5-alpha reduction, this non-aromatizing, non-progestogenic agent delivers the hard, grainy muscularity historically associated with elite-level conditioning compounds—yet with substantially greater anabolic potency than Methenolone and a markedly cleaner side-effect profile than more aggressive androgens.
Each milliliter of Dragon Pharma's pharmaceutical-grade formulation provides precisely 100mg of Dihydroboldenone Cypionate, manufactured under stringent quality-control protocols to ensure sterility, potency, and batch-to-batch consistency. For competitors, experienced bodybuilders, and aesthetic-focused athletes who refuse to compromise on definition while still demanding meaningful hypertrophic progress, this compound offers a refined pathway to substantial, maintainable lean mass without the estrogenic complications that obscure muscular detail.
What is Dragon Pharma 1-Test Cyp?
1-Test Cyp, scientifically designated as Dihydroboldenone Cypionate, is a synthetic injectable anabolic-androgenic steroid representing the 5-alpha-reduced derivative of Boldenone Undecylenate—analogous to the relationship between dihydrotestosterone and testosterone. This critical structural modification eliminates the compound's ability to interact with the aromatase enzyme, rendering it completely non-estrogenic, while simultaneously increasing its androgen receptor binding affinity and anabolic potency. The cypionate ester extends the active half-life to approximately 10–14 days, supporting convenient twice-weekly injection schedules and stable plasma concentrations over extended protocols.
It is essential to distinguish this agent from Boldenone Undecylenate (Equipoise): while EQ is prized for erythropoietic enhancement and endurance, 1-Test Cyp is optimized for direct myotrophic activity, producing dry, dense tissue accretion with minimal hematocrit manipulation. The "1-Test" nomenclature refers to the double bond at the first carbon position, a structural feature that sterically prevents aromatization and contributes to the compound's exceptionally high anabolic rating. Dragon Pharma's oil-based injectable formulation delivers this advanced agent with pharmaceutical precision for intramuscular administration.
Key Benefits / Effects
- High-Density Lean Hypertrophy: Users experience steady, sustainable accretion of pure contractile tissue—typically 8–15 pounds over a 14–16 week cycle—characterized by exceptional hardness and minimal fluid retention that persists post-cycle.
- Exceptional Muscular Graininess: As a DHT-derived compound, 1-Test Cyp promotes a distinctly hard, granular, and striated aesthetic prized in competitive bodybuilding, with muscles appearing carved and three-dimensional even at rest.
- Enhanced Venous Prominence: Absence of subcutaneous water retention combined with improved nutrient partitioning produces pronounced vascularity, with new vein patterns frequently emerging across deltoids, arms, and quadriceps.
- Reliable Strength Progression: While not as explosively potent as Oxymetholone or Trenbolone, the compound delivers consistent, incremental increases in compound lift performance that correlate directly with accrued lean tissue.
- Superior Nutrient Partitioning: The anabolic environment directs dietary calories preferentially toward muscle glycogen and protein synthesis rather than adipose storage, improving the efficiency of both surplus and maintenance phases.
- Complete Estrogenic Immunity: Non-aromatizing and non-progestogenic structure eliminates gynecomastia risk, water retention, estrogenic blood pressure elevation, and the need for aromatase inhibitor management of the compound itself.
How Dragon Pharma 1-Test Cyp Works
Dihydroboldenone Cypionate initiates its anabolic effects through high-affinity binding to androgen receptors within skeletal myocytes, upregulating the transcription of muscle-specific genes involved in protein synthesis, nitrogen retention, and satellite cell activation. The 5-alpha-reduced structure—sharing the DHT backbone—confers strong androgenic character while the C1–C2 double bond prevents aromatase enzyme recognition, ensuring that all receptor-mediated activity occurs within a purely androgenic environment devoid of estrogenic signaling.
The cypionate ester undergoes gradual enzymatic cleavage in plasma, releasing free Dihydroboldenone at a sustained rate that maintains elevated anabolic blood levels for 10–14 days between administrations. This steady-state pharmacokinetics supports continuous positive nitrogen balance, enhanced myofibrillar contractile density, and progressive muscular adaptation without the hormonal fluctuations associated with shorter esters.
Additionally, the compound improves insulin sensitivity at the muscular level, facilitating more efficient glucose uptake and glycogen supercompensation that contributes to the full, hard appearance characteristic of DHT-derived agents. The net physiological outcome is a slow-building yet profoundly refined hypertrophy that manifests as quality rather than quantity.
Usage Information
Dragon Pharma 1-Test Cyp is supplied as a 100mg per milliliter oil-based injectable solution, designed exclusively for intramuscular administration. Due to the extended half-life of the cypionate ester, injections should be administered twice weekly—typically every 3.5 days—to maintain stable plasma concentrations and minimize hormonal fluctuation. Beginner and intermediate users generally employ 400–600mg weekly, divided into two equal injections of 200–300mg.
Advanced practitioners may escalate to 600–800mg weekly, with a minority of highly experienced users exploring 1000mg weekly under comprehensive health monitoring. Because Dihydroboldenone suppresses endogenous testosterone production, a testosterone base is absolutely mandatory—Testosterone Cypionate at 400–500mg weekly represents an ideal pairing due to ester compatibility and synergistic anabolic signaling. Cycle duration should be a minimum of 12 weeks, with 14–16 weeks considered optimal to fully capitalize on the compound's slow-building nature. Post-Cycle Therapy must commence approximately two weeks after the final injection, accounting for cypionate ester clearance. Intramuscular injections should rotate between gluteal, deltoid, and vastus lateralis sites to prevent localized tissue irritation.
Quality & Manufacturing
Dragon Pharma enforces uncompromising pharmaceutical manufacturing standards across all injectable production lines, with each batch of Dihydroboldenone Cypionate subjected to independent third-party laboratory analysis to verify sterility, active ingredient concentration, heavy metal absence, and endotoxin levels. The 100mg per milliliter oil-based solution is formulated with pharmaceutical-grade carrier oils and precise ester attachment, ensuring consistent pharmacokinetics and minimal injection site reaction.
Dihydroboldenone synthesis is notably more complex than standard testosterone esterification, making this compound particularly susceptible to underdosing or contamination in unregulated laboratory environments. Dragon Pharma's analytical transparency and batch verification ensure that each vial delivers exactly the stated 100mg per milliliter potency, eliminating the uncertainty that compromises results and safety when sourcing from underground or unverified suppliers. This manufacturing integrity is essential for athletes programming 14–16 week cycles where dosing consistency directly influences the quality and sustainability of physique outcomes.
Possible Side Effects / Safety Information
- Androgenic Dermatological Effects: As a DHT-derived compound, 1-Test Cyp can increase sebaceous gland activity causing oily skin and acne, accelerate androgenic alopecia in genetically predisposed individuals, and stimulate terminal hair growth.
- Cardiovascular Dyslipidemia: The compound may modestly depress HDL cholesterol while elevating LDL cholesterol, though this effect is generally less severe than with Trenbolone or oral C17-aa steroids. Dietary omega-3 supplementation and regular cardiovascular exercise are advisable.
- Profound HPTA Suppression: Like all anabolic steroids except select DHT derivatives, Dihydroboldenone suppresses endogenous testosterone production completely. A testosterone base during the cycle and comprehensive PCT afterward are absolutely mandatory.
- Low Estrogen Manifestations: When stacked exclusively with non-aromatizing compounds, the absence of estrogen can produce dry joints, diminished libido, and mood disturbances. A moderate testosterone base mitigates these symptoms.
- Injection Site Discomfort: The cypionate ester in oil carrier is generally well-tolerated, though occasional post-injection pain, warmth, or minor swelling may occur, particularly with suboptimal injection technique.
- Absence of Estrogenic Risk: The non-aromatizing, non-progestogenic structure completely eliminates gynecomastia, water retention, and estrogenic hypertension—representing one of the compound's primary safety advantages.
Why Choose Dragon Pharma 1-Test Cyp?
In an industry where complex compounds like Dihydroboldenone are frequently underdosed, mislabeled as simpler Boldenone, or contaminated with heavy metals and bacterial endotoxins, Dragon Pharma's commitment to analytical verification and sterile manufacturing provides an essential layer of trust. The precise 100mg per milliliter concentration ensures that athletes can program extended 14–16 week cycles with mathematical confidence, knowing that each injection delivers exactly the pharmacological payload required for steady, quality tissue accretion.
For bodybuilders who have progressed beyond basic bulking and seek to craft a physique defined by density, separation, and vascular clarity—without the estrogenic management burden of aromatizing compounds—this verified formulation represents an indispensable tool. The combination of DHT-derived hardness, non-aromatizing cleanliness, and cypionate ester convenience creates a unique value proposition for the aesthetic-focused athlete.
Product FAQ
Questions, answered
While chemically related as 5-alpha-reduced and non-reduced variants, these compounds produce distinctly different physiological outcomes. Boldenone Undecylenate is characterized by pronounced erythropoiesis, increased appetite, and steady but relatively mild anabolic effects with significant water retention potential. Dihydroboldenone Cypionate lacks the endurance and hematocrit benefits of EQ but delivers substantially greater anabolic potency, complete absence of aromatization, and a much harder, drier aesthetic. Think of EQ as an endurance and mass-building tool, while 1-Test Cyp is a precision instrument for lean, dense hypertrophy and competition conditioning.
Dihydroboldenone suppresses the hypothalamic-pituitary-gonadal axis rapidly and completely, shutting down endogenous testosterone production. Without exogenous testosterone replacement, users experience severe low-androgen symptoms including lethargy, libido collapse, erectile dysfunction, joint pain, and depression. A testosterone base—typically 400–500mg weekly of Testosterone Cypionate or Enanthate—maintains physiological androgen levels, preserving mental clarity, sexual function, and quality of life while 1-Test Cyp drives lean tissue development. The matching cypionate ester also simplifies injection scheduling.
Unlike rapid-acting oral steroids or short-ester injectables, 1-Test Cyp produces steady, cumulative effects that build progressively over the first several weeks. Most users notice improved training pumps, enhanced vascularity, and modest strength increases by week 3–4. Visible lean mass changes and density improvements typically consolidate between weeks 6 and 10, with maximal results appearing during weeks 12–16. The slow onset is a trade-off for the exceptionally high quality and sustainability of the gains produced.
For ultimate dry, high-quality hypertrophy, stack 1-Test Cyp at 600mg weekly with Methenolone Enanthate (Primobolan) at 400–600mg weekly. This combination creates a powerful synergy of non-aromatizing DHT-derived compounds that produce incredibly dense, grainy muscle with virtually no water retention. Adding an oral kickstarter such as Oxandrolone at 50mg daily for the first 6 weeks can accelerate early results without introducing estrogenic complications. A testosterone base at 400mg weekly underpins the stack, with a low-dose aromatase inhibitor available for estrogen management from the testosterone component.
No. The 5-alpha-reduced structure and C1–C2 double bond completely prevent interaction with the aromatase enzyme, eliminating any possibility of estrogen conversion. Additionally, the compound possesses no affinity for progesterone receptors, removing progestogenic gynecomastia risk as well. Users will not experience subcutaneous water retention, bloating, or estrogenic blood pressure elevation from Dihydroboldenone itself. However, any concurrent testosterone base will aromatize and may require aromatase inhibitor management.
While generally considered less cardiotoxic than Trenbolone or oral C17-alpha alkylated steroids, Dihydroboldenone can still produce unfavorable shifts in lipid profiles, including modest HDL depression and potential LDL elevation. These effects are typically manageable through dietary intervention—emphasizing omega-3 fatty acids, soluble fiber, and antioxidant-rich foods—combined with regular low-intensity cardiovascular exercise. Pre-cycle, mid-cycle, and post-cycle lipid panels are recommended for comprehensive cardiovascular oversight, particularly at advanced doses approaching 800–1000mg weekly.
PCT must account for the cypionate ester's 10–14 day active half-life, meaning therapy should begin approximately 14 days after the final injection. A comprehensive protocol includes Clomiphene Citrate at 50/50/25/25mg and Tamoxifen Citrate at 40/20/20/20mg over four weeks. HCG at 500–1000IU every other day for the two weeks preceding SERM initiation can prime testicular responsiveness. Because cycles are typically 14–16 weeks, recovery may be more gradual than after shorter protocols, and blood work confirming restored LH, FSH, and total testosterone should precede any subsequent cycle.
Absolutely. The compound's non-aromatizing nature, absence of fluid retention, and enhancement of nutrient partitioning make it exceptionally valuable during hypocaloric cutting phases. It preserves existing lean muscle tissue with remarkable efficiency while supporting strength maintenance and training intensity despite energy deficit. When stacked with non-aromatizing cutting agents such as Drostanolone or Trenbolone Acetate, 1-Test Cyp contributes to a competition-ready aesthetic of extreme hardness, separation, and vascularity.
Both compounds are non-aromatizing DHT-derived agents prized for dry, high-quality aesthetics, but 1-Test Cyp offers significantly greater anabolic potency on a milligram-for-milligram basis. While Methenolone is exceptionally mild and well-tolerated, it requires higher doses and longer cycles to produce comparable hypertrophy. Dihydroboldenone delivers similar grainy hardness and density but with more pronounced strength increases and lean mass accretion. Primobolan remains the safer, more conservative choice for beginners and long-term health-conscious users, while 1-Test Cyp suits experienced athletes seeking greater anabolic drive without estrogenic compromise.
Despite the 10–14 day active half-life, most experienced users administer 1-Test Cyp twice weekly to maintain stable plasma concentrations and minimize hormonal fluctuation. A Monday/Thursday or Tuesday/Friday injection schedule works well for weekly dosages of 400–600mg. More frequent administration—such as every other day—may further smooth blood levels but is generally unnecessary given the ester's slow release kinetics. Users should rotate injection sites among gluteal, deltoid, and vastus lateralis muscles to prevent localized scar tissue accumulation.
Female use is possible at significantly reduced doses due to the compound's DHT-derived structure, though virilization risk is real and dose-dependent. Women who choose to experiment should limit doses to 50–100mg weekly, divided into small twice-weekly injections, and restrict cycle duration to 6–8 weeks. Early monitoring for voice deepening, clitoral enlargement, facial hair growth, and menstrual disruption is essential, with immediate cessation required upon symptom onset. Given the limited female-specific data, conservative caution is strongly advised.
Comprehensive panels should include total and free testosterone, estradiol, complete blood count with hematocrit, comprehensive metabolic panel with liver enzymes, and a full lipid profile. Baseline testing before cycle initiation establishes reference ranges. Mid-cycle assessment at week 8 identifies emerging dyslipidemia or hematocrit elevation. Post-cycle testing at weeks 3 and 6 after the final injection confirms hormonal recovery. Given the extended cycle lengths typical of this compound, quarterly monitoring is prudent for athletes running 16-week protocols.
